TBIO: Codex DNA Price-to-Revenue Coefficient
Telesis Bio, Inc. (TBIO) generates revenue through the sale of automated gene synthesizers and related materials. The median P/S from GURU.Markets is used to analyze the trend, where the metric value is 0.30. While the environmental efficiency of the systems reduces the carbon footprint of laboratories, operating losses and slow technology adoption create significant risks for the company's capitalization within the synthetic biology sector.
Metric breakdowns and analytics for Codex DNA (TBIO)
- current price and projected stock value:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Telesis Bio, Inc.|TBIO - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Telesis Bio, Inc|TBIO - Company Aggregate Debts|Debt to Book Value Codex DNA|TBIO - Company Long-Term Liabilities|Short-Term Debt Volume Telesis Bio|Intermediate Liquidity Ratio telesisbio.com
- earnings and multiples data:
TBIO - Net Profit|Expected Profit Telesis Bio, Inc.|TBIO - P/E Multiple|Market Cap to Projected Earnings Telesis Bio Inc.|TBIO - Price/Earnings to Growth Ratio|Company Value to EBITDA Codex DNA|TBIO - Operating profit EBITDA|Earnings per share for the last 12 months Telesis Bio|TBIO - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months telesisbio.com|TBIO - Earnings growth in current year|Earnings growth forecast for next year Telesis Bio, Inc.
- sales revenue and business income indicators:
General company analysis:TBIO (telesisbio.com)
The efficiency of DNA synthesis system logistics and reagent supplies directly impacts the price-to-sales valuation of Telesis Bio, Inc. (TBIO). This multiple compares the company's total market capitalization to its annual revenue, allowing investors to identify asset overheating when quotes deviate from historical norms and determine the equilibrium point to assess the stability of invested capital.
Who Telesis Bio, Inc. competes with
Price-to-Revenue Ratio TEM (Tempus AI)|P/S Multiple QGEN (Qiagen)|Price-to-Revenue Coefficient Ionis Pharmaceuticals, Inc. (IONS)|RGEN - Price-to-Revenue Ratio|Price to Sales Avidity Corp|CRSP (CRISPR Therapeutics AG) - Market Cap to Revenue|genedx.com - Market Capitalization-to-Revenue Ratio|RARE (Ultragenyx) - P/S Multiple|Beam Therapeutics Inc (BEAM) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience Corp - Market Cap to Revenue Ratio|P/S Multiple TXG (10x Genomics, Inc.)|NTLA - Market Cap to Revenue|STOK: Market Cap to Revenue|Price-to-Revenue Coefficient BioLife Solutions Inc BLFS|WVE (Wave Life Sciences Corp) - Market Cap to Revenue|MAZE: Market Cap to Sales Volume|SION (Sionna Therapeutics Inc) - P/S Multiple|Price-to-Revenue Ratio PRME|P/S Multiple TSHA|Price-to-Revenue Coefficient uniQure NV|Price-to-Revenue Ratio MeiraGTx PLC MGTX|REGENXBIO Corp (RGNX) - Price to Sales|Solid Biosciences Inc. - P/S Multiple|OCGN (ocugen.com) - Market Cap to Revenue Ratio|PacBio (PACB) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio BNTC|DSGN (Design Pharma) - P/S Multiple|P/S Multiple Rocket Corp|Market Cap to Revenue FDMT (4D Molecular Therapeutics)|Market Cap to Sales Volume LXEO|P/S Multiple KRRO (Korro Bio)|Editas Medicine Inc (EDIT) - Price to Sales|SLN - Price-to-Revenue Ratio|PRQR: Price-to-Revenue Ratio|CDXS: P/S Multiple|Price to Sales sangamo.com (SGMO)|Price-to-Revenue Ratio Nautilus Biotechnology, Inc.|Metagenomi Inc. (MGX) - Price-to-Revenue Coefficient|P/S Multiple DTIL|Price-to-Revenue Coefficient generationbio.com|Price-to-Revenue Ratio Boundless Bio, Inc. BOLD|Price-to-Revenue Coefficient Exicure Inc. (XCUR)|IMNN: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PHIO (Phio Pharmaceuticals)|MBIO: P/S Multiple|RNAZ (TransCode Therapeutics, Inc.) - Price-to-Revenue Ratio|BNGO (Bionano Genomics Inc.) - P/S Multiple|adnas.com (APDN) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio bluebird bio (BLUE)|IPA - Price to Sales|Omega - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio OMIC|Regulus Therapeutics - P/S Multiple|Price-to-Revenue Coefficient syros.com SYRS|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio UBX
